Business
Medexus Highlights Data on Trecondyv (Treosulfan) Presented at MDS 2023
Princess Margaret Cancer Center's retrospective analysis found a 30% improvement (83.2% vs 53.2%)...
About this update from Medexus Pharmaceuticals Inc.
[{"type":"text","content":"Medexus Highlights Data on Trecondyv (Treosulfan) Presented at MDS 2023Princess Margaret Cancer Center's retrospective analysis found a 30% improvement (83.2% vs 53.2%) in one-year overall survival for patients treated with treosulfan, among other positive findingsToronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 13, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to highlight positive new data on treosulfan that researchers at Toronto's Princess Margaret Hospital (PMH) recently presented at MDS 2023, the 17th annual International Congress on Myelodysplastic Syndromes, held in Marseille, France. The study, a retrospective analysis of patient outcomes, further confirms Medexus's optimism regarding treosulfan's potential positive impact in both Canada and the United States.The study found that reduced toxicity conditioning (RTC) with fludarabine-treosulfan (FT) improves transplant outcomes in myeloablative conditioning (MAC) ineligible patients with myelodysplastic syndrome (MDS) who receive graft-vs-host disease (GVHD) prophylaxis with dual T-cell depletion (TCD). Notably, the study found a 30% improvement (83.2% vs 53.2%) in one-year overall survival for patients treated with treosulfan, among other positive findings. See \"About the study\" below for additional information about the study's methods, results, and conclusions, including information about the study's design and a summary of selected statistical information.\"We are very encouraged by these new results of PMH's study, which are consistent with previous studies and further demonstrate the potential benefits of treosulfan,\" said Ken d'Entremont, Medexus's Chief Executive Officer. \"We see this latest evidence as yet another important indicator of this product's prospects, including because we view these results as equally relevant to patient communities in the United States market.\"\"Clinicians should always make the best choice possible for their patients, so we are very pleased with the data we presented at MDS 2023, as it further underscores the clinical and therapeutic utility of treosulfan,\" added Dr Ivan Pasic from PMH.The full abstract, which includes further discussion of the study's design and findings, was published in the Leukemia Research journal and is available at the following link: https://doi.org/10.1016/j.leukres...